Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

News SummaryMost relevantAll newsSector news 

FDA Concludes Safety Review Of Novartis MS Drug Gilenya

share with twitter share with LinkedIn share with facebook
share via e-mail
05/14/2012 | 06:55pm CET

--FDA concludes safety review of MS drug Gilenya

--FDA advises against use in certain heart and stroke patients

--FDA says no clear link between Gilenya and cardiovascular deaths

(Updates with additional background on EMA review starting in seventh paragraph and information on experimental Biogen Idec MS drug.)

   By Jennifer Corbett Dooren 

The U.S. Food and Drug Administration Monday said Novartis AG's (NVS, NOVN.VX) multiple-sclerosis drug Gilenya shouldn't be used in patients with a recent history of stroke or some types of heart problems, concluding a safety review of the drug.

The safety review was prompted by a report last November of a 59-year-old patient dying in the U.S. less than 24 hours after taking the first dose of the drug.

The agency said it continues to recommend that doctors closely monitor the hearts of patients after they have been given the first dose of the drug because the product can lower a person's heart rate temporarily.

As for the patient's death, the FDA said an exact cause of death couldn't be identified. The FDA said the patient had extensive brainstem MS lesions, which also have been associated with sudden death. The FDA also said it looked at other deaths that appeared to be from cardiovascular causes in patients who had been taking Gilenya and concluded that the drug's "contribution to the death was unclear."

The FDA said the drug shouldn't be used in patients who have had a stroke or heart trouble within the past six months. The agency also said the drug shouldn't be used in patients taking some kinds of antiarrhythmic heart medicines.

Europe's drug regulator, the European Medicines Agency, last month requested stronger safety warnings for Gilenya after the agency concluded its review of the drug.

Gilenya is currently the only oral MS drug on the market but its sales prospects have been clouded by recent safety concerns. It was approved in the U.S. in 2010 and has been available in Europe since 2011.

The product is designed to treat patients with the relapsing form of MS, which is a progressive disease that involves damage to the nerves controlling muscles and vision.

The FDA is currently reviewing another oral MS drug from Biogen Idec Inc. (BIIB) called BG-12 that is designed to work through a different mechanism than Gilenya. Biogen Idec last week announced that the FDA accepted BG-12's new drug application for a standard 10-month review, which sets an agency decision deadline of about Dec. 28.

-By Jennifer Corbett Dooren; Dow Jones Newswires, 202-862-9294; jennifer.corbett@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on NOVARTIS AG
07:16a NOVARTIS : ' Lucentis® received EU approval in new indication - Lucentis the onl..
12/06 NOVARTIS : GEMS school creates ‘World’s Largest Human Image of an Or..
12/06 NOVARTIS : announces Zykadia® first-line study results showing 16.6 month progre..
12/05 Une offre de Novartis sur Actelion jugée peu probable
12/05 NOVARTIS : data shows Treatment-free Remission rates are consistently above 50% ..
12/05 NOVARTIS : survey uncovers real-world burden of myeloproliferative neoplasms (ra..
12/05 NOVARTIS : Selexys exit validates Oklahoma as place to start biotech firms
12/05 NOVARTIS : SEG101 (crizanlizumab, formerly SelG1) significantly reduces frequenc..
12/05 OXFORD BIOMEDICA : Notes Positive Novartis CTL019 Findings
12/05 NOVARTIS : SEG101 (crizanlizumab, formerly SelG1) significantly reduces frequenc..
More news
Sector news : Pharmaceuticals - NEC
10:29a PFIZER : Britain fines Pfizer record $107 million for huge drug price hike
12/06DJNovo Nordisk Pledges to Limit Price Increases in U.S. for Its Drugs
12/06DJSANOFI : Big Pharma, Short on Blockbusters, Outsources the -2-
12/06DJSANOFI : Big Pharma, Short on Blockbusters, Outsources the Science
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
12/06 Novartis' Zykadia beats chemo in late-stage lung cancer study
12/05 Novartis Makes Its Case For Driving A CAR Into The Real World
12/05 BIOTECH FORUM DAILY DIGEST : Biotech Has Tough Week; Will Conference Buoy Immuno..
12/05 Avillion's BOSULIF beats Gleevec in late-stage study in type of leukemia; lic..
12/05 WALL STREET BREAKFAST : Investors Shrug Off Italy's Referendum Result
Financials ($)
Sales 2016 48 805 M
EBIT 2016 11 857 M
Net income 2016 8 046 M
Debt 2016 15 084 M
Yield 2016 4,12%
P/E ratio 2016 19,89
P/E ratio 2017 18,71
EV / Sales 2016 4,01x
EV / Sales 2017 3,92x
Capitalization 180 387 M
More Financials
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 83,3 $
Spread / Average Target 21%
Consensus details
EPS Revisions
More Estimates Revisions
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG-20.79%180 387
JOHNSON & JOHNSON9.09%304 863
PFIZER INC.-2.23%191 517
ROCHE HOLDING LTD.-19.65%190 397
MERCK & CO., INC.14.12%166 200
SANOFI-4.20%104 405
More Results